|Bid||150.00 x 2200|
|Ask||151.20 x 800|
|Day's Range||146.22 - 150.32|
|52 Week Range||35.25 - 152.87|
|Beta (5Y Monthly)||1.65|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 09, 2021 - Feb 15, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||154.79|
In this article, we present to you the 15 Best Undervalued Stocks to Buy Now. If you’re in a hurry, click to skip ahead and jump to the 5 Best Undervalued Stocks to Buy Now. Investing in the stock market could be difficult. We can classify investors based on their portfolios. The low risk-takers who […]
Exact Sciences' (EXAS) strength in Screening revenue along with a robust COVID-19 testing arm are likely to have boosted the top line significantly.
Exact Sciences Corp. (Nasdaq: EXAS) today announced that it has acquired a worldwide exclusive license to the proprietary TARDIS technology from The Translational Genomics Research Institute (TGen), an affiliate of City of Hope. This compelling and technically distinct approach will help expand Exact Sciences' leadership in precision oncology and offers a differentiated patient-specific solution in minimal residual disease testing.